NCT07842601Not yet recruiting
Helping Kentuckians Overcome Depression and Opioid Addiction With Brain Stimulation
Source: ClinicalTrials.gov · Last updated 25 Sept 2026
Brief summary (registry, in English)
This study will compare transcranial magnetic stimulation (TMS) with sham TMS in people with opioid use disorder who are taking buprenorphine and have major depressive disorder with ongoing depressive symptoms. The study will evaluate whether TMS improves depressive symptoms and reduces opioid craving. The study will also assess smoking behaviors, treatment acceptability, and any side effects related to TMS.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 21 Sept 2026
- Start date
- 15 Oct 2026
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- University of Kentucky
- Diseases
- Depression
- NCT number
- NCT07842601
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 15 Oct 2026 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Magnetic resonance imaging (MRI) contraindications, including ferrous retainers, intracranial implants, or claustrophobia
- Surgical procedure planned during the study period
Other illness
- Seizure disorder
- any other acute medical or behavioral disorder that would preclude safe participation
- Any other medical condition that could compromise participant well-being
Other
- Pregnant, nursing or planning to become pregnant during the study
Who the study is looking for
- 18-75 years of age
- Willing and able to provide informed consent
- Able to read and speak english
- Opioid use disorder, in remission for at least a month
- Diagnosis of major depressive disorder confirmed with the Mini-International Neuropsychiatric Interview (MINI, 7.02)
- Minimum score of 10 on the 17-item Hamilton Depression Rating Scale (HDRS-17)
- Opioid craving score of 5 or greater on a 0-10 scale
- Stabilized on sublingual or depot buprenorphine for at least 8 weeks
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Kentucky Coordinator of this site? Confirm its status | Lexington | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.